Axel Hoos was interviewed in January and he made a few points very clear about GSK's oncology programme.
There are some things GSK won’t do in oncology R&D, including their own PD-1 program.
“We will not be a leader in PD-1,” he says. “We have no illusions and it makes no sense.” And there’s no IDO, no CD-19 program, also areas where leaders are well advanced in the field.
And the hunt is on for synergistic tech that can be used to help advance these new platform drugs, with an eye to making the cancer operation profitable after gaining the first new approvals.
https://endpts.com/gsks-long-quiet-...se-as-it-mounts-a-breakout-late-stage-effort/
- Forums
- ASX - By Stock
- IMU
- Melbourne event April 3rd
Melbourne event April 3rd, page-77
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
(20min delay)
|
|||||
Last
5.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $404.2M |
Open | High | Low | Value | Volume |
5.6¢ | 5.6¢ | 5.5¢ | $399.1K | 7.236M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 201018 | 5.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.6¢ | 749859 | 7 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 201018 | 0.055 |
17 | 2191168 | 0.054 |
11 | 800647 | 0.053 |
19 | 1659549 | 0.052 |
18 | 2560434 | 0.051 |
Price($) | Vol. | No. |
---|---|---|
0.056 | 749859 | 7 |
0.057 | 270444 | 2 |
0.058 | 725000 | 4 |
0.059 | 961714 | 3 |
0.060 | 888850 | 11 |
Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |